Analysts’ Recent Ratings Updates for Amgen (AMGN)

A number of firms have modified their ratings and price targets on shares of Amgen (NASDAQ: AMGN) recently:

• 5/20/2026 – Amgen had its price target lowered by Argus from $400.00 to $375.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Amgen had its price target lowered by Piper Sandler from $432.00 to $427.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Amgen had its price target lowered by Daiwa Securities Group Inc. from $410.00 to $390.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Amgen was upgraded by Freedom Capital from “hold” to “strong-buy”.
• 5/5/2026 – Amgen had its “hold” rating reaffirmed by Erste Group Bank AG.
• 5/4/2026 – Amgen had its price target lowered by Guggenheim from $351.00 to $340.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Amgen was given a new $332.00 price target by Morgan Stanley.
• 5/1/2026 – Amgen had its price target raised by Truist Financial Corporation from $325.00 to $327.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Amgen had its price target raised by The Goldman Sachs Group, Inc. from $415.00 to $425.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Amgen had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an “equal weight” rating on the stock.
• 4/25/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/20/2026 – Amgen is now covered by Canaccord Genuity Group Inc.. They set a “hold” rating and a $366.00 price target on the stock.
• 4/13/2026 – Amgen had its price target raised by UBS Group AG from $390.00 to $400.00. They now have a “buy” rating on the stock.
• 4/11/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/10/2026 – Amgen had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an “equal weight” rating on the stock.
• 4/9/2026 – Amgen had its price target raised by Guggenheim from $347.00 to $351.00. They now have a “neutral” rating on the stock.
• 4/8/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
• 4/7/2026 – Amgen had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an “outperform” rating on the stock.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen’s payout ratio is presently 70.15%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is owned by insiders.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.